Overview

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status:
Recruiting

Trial end date:
2023-02-28

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D), and safety and tolerability of zanubrutinib in combination with lenalidomide in participants with R/R DLBCL by dose escalating lenalidomide

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Treatments:

Lenalidomide
Rituximab
Zanubrutinib